Shakun Karki1, Melissa G Farb1, Doan T M Ngo1, Samantha Myers1, Vishwajeet Puri1, Naomi M Hamburg1, Brian Carmine1, Donald T Hess1, Noyan Gokce2. 1. From the Evans Department of Medicine and Whitaker Cardiovascular Institute (S.K., M.G.F., D.T.M.N., S.M., V.P., N.M.H., N.G.) and Department of General Surgery (B.C., D.T.H.), Boston University School of Medicine, MA. 2. From the Evans Department of Medicine and Whitaker Cardiovascular Institute (S.K., M.G.F., D.T.M.N., S.M., V.P., N.M.H., N.G.) and Department of General Surgery (B.C., D.T.H.), Boston University School of Medicine, MA. Noyan.Gokce@bmc.org.
Abstract
OBJECTIVE: Increased visceral adiposity has been closely linked to insulin resistance, endothelial dysfunction, and cardiometabolic disease in obesity, but pathophysiological mechanisms are poorly understood. We sought to investigate mechanisms of vascular insulin resistance by characterizing depot-specific insulin responses and gain evidence that altered functionality of transcription factor forkhead box O-1 (FOXO-1) may play an important role in obesity-related endothelial dysfunction. APPROACH AND RESULTS: We intraoperatively collected paired subcutaneous and visceral adipose tissue samples from 56 severely obese (body mass index, 43 ± 7 kg/m(2)) and 14 nonobese subjects during planned surgical operations, and characterized depot-specific insulin-mediated responses using Western blot and quantitative immunofluorescence techniques. Insulin signaling via phosphorylation of FOXO-1 and consequent endothelial nitric oxide synthase stimulation was selectively impaired in the visceral compared with subcutaneous adipose tissue and endothelial cells of obese subjects. In contrast, tissue actions of insulin were preserved in nonobese individuals. Pharmacological antagonism with AS1842856 and biological silencing using small interfering RNA-mediated FOXO-1 knockdown reversed insulin resistance and restored endothelial nitric oxide synthase activation in the obese. CONCLUSIONS: We observed profound endothelial insulin resistance in the visceral adipose tissue of obese humans which improved with FOXO-1 inhibition. FOXO-1 modulation may represent a novel therapeutic target to diminish vascular insulin resistance. In addition, characterization of endothelial insulin resistance in the adipose microenvironment may provide clues to mechanisms of systemic disease in human obesity.
OBJECTIVE: Increased visceral adiposity has been closely linked to insulin resistance, endothelial dysfunction, and cardiometabolic disease in obesity, but pathophysiological mechanisms are poorly understood. We sought to investigate mechanisms of vascular insulin resistance by characterizing depot-specific insulin responses and gain evidence that altered functionality of transcription factor forkhead box O-1 (FOXO-1) may play an important role in obesity-related endothelial dysfunction. APPROACH AND RESULTS: We intraoperatively collected paired subcutaneous and visceral adipose tissue samples from 56 severely obese (body mass index, 43 ± 7 kg/m(2)) and 14 nonobese subjects during planned surgical operations, and characterized depot-specific insulin-mediated responses using Western blot and quantitative immunofluorescence techniques. Insulin signaling via phosphorylation of FOXO-1 and consequent endothelial nitric oxide synthase stimulation was selectively impaired in the visceral compared with subcutaneous adipose tissue and endothelial cells of obese subjects. In contrast, tissue actions of insulin were preserved in nonobese individuals. Pharmacological antagonism with AS1842856 and biological silencing using small interfering RNA-mediated FOXO-1 knockdown reversed insulin resistance and restored endothelial nitric oxide synthase activation in the obese. CONCLUSIONS: We observed profound endothelial insulin resistance in the visceral adipose tissue of obesehumans which improved with FOXO-1 inhibition. FOXO-1 modulation may represent a novel therapeutic target to diminish vascular insulin resistance. In addition, characterization of endothelial insulin resistance in the adipose microenvironment may provide clues to mechanisms of systemic disease in humanobesity.
Authors: Kyoichiro Tsuchiya; Jun Tanaka; Yu Shuiqing; Carrie L Welch; Ronald A DePinho; Ira Tabas; Alan R Tall; Ira J Goldberg; Domenico Accili Journal: Cell Metab Date: 2012-03-07 Impact factor: 27.287
Authors: Kodlipet Dharmashankar; Aimee Welsh; Jingli Wang; Tinoy J Kizhakekuttu; Rong Ying; David D Gutterman; Michael E Widlansky Journal: Am J Hypertens Date: 2012-02-16 Impact factor: 2.689
Authors: Lin Piao; Vaninder K Sidhu; Yong-Hu Fang; John J Ryan; Kishan S Parikh; Zhigang Hong; Peter T Toth; Erik Morrow; Shelby Kutty; Gary D Lopaschuk; Stephen L Archer Journal: J Mol Med (Berl) Date: 2012-12-18 Impact factor: 4.599
Authors: David Vicent; Jacob Ilany; Tatsuya Kondo; Keiko Naruse; Simon J Fisher; Yaz Y Kisanuki; Sven Bursell; Masashi Yanagisawa; George L King; C Ronald Kahn Journal: J Clin Invest Date: 2003-05 Impact factor: 14.808
Authors: Jun Tanaka; Li Qiang; Alexander S Banks; Carrie L Welch; Michihiro Matsumoto; Tadahiro Kitamura; Yukari Ido-Kitamura; Ronald A DePinho; Domenico Accili Journal: Diabetes Date: 2009-07-07 Impact factor: 9.461
Authors: Doan T M Ngo; Aaron L Sverdlov; Shakun Karki; Donia Macartney-Coxson; Richard S Stubbs; Melissa G Farb; Brian Carmine; Donald T Hess; Wilson S Colucci; Noyan Gokce Journal: Am J Physiol Endocrinol Metab Date: 2018-12-21 Impact factor: 4.310
Authors: Shakun Karki; Doan T M Ngo; Melissa G Farb; Song Young Park; Samantha M Saggese; Naomi M Hamburg; Brian Carmine; Donald T Hess; Kenneth Walsh; Noyan Gokce Journal: Am J Physiol Heart Circ Physiol Date: 2017-04-14 Impact factor: 4.733
Authors: Melissa G Farb; Shakun Karki; Song-Young Park; Samantha M Saggese; Brian Carmine; Donald T Hess; Caroline Apovian; Jessica L Fetterman; Rosa Bretón-Romero; Naomi M Hamburg; José J Fuster; María A Zuriaga; Kenneth Walsh; Noyan Gokce Journal: Vasc Med Date: 2016-09-28 Impact factor: 3.239